Literature DB >> 35732856

MERCI: a machine learning approach to identifying hydroxychloroquine retinopathy using mfERG.

Faisal Habib1, Huaxiong Huang1,2,3,4, Arvind Gupta1, Tom Wright5,6.   

Abstract

PURPOSE: Hydroxychloroquine (HCQ) is an anti-inflammatory drug in widespread use for the treatment of systemic auto-immune diseases. Vision loss caused by retinal toxicity is a significant risk associated with long term HCQ therapy. Identifying patients at risk of developing retinal toxicity can help prevent vision loss and improve the quality of life for patients. This paper presents updated reference thresholds and examines the diagnostic accuracy of a machine learning approach for identifying retinal toxicity using the multifocal Electroretinogram (mfERG).
METHODS: A retrospective study of patients referred for mfERG testing to detect HCQ retinopathy. A consecutive series of all patients referred to Kensington Vision and Research Centre between August 2017 and July 2020 were considered eligible. Eyes suspect for other ocular pathology including widespread retinal disease and advanced macular pathology unrelated to HCQ or with poor quality mfERG recordings were excluded. All patients received mfERG testing and Ocular Coherence Tomography (OCT) imaging. Presence of HCQ retinopathy was based on ring ratio analysis using clinical reference thresholds established at KVRC coupled with structural features observed on OCT, the clinical reference standard. A Support Vector Machine (SVM) using selected features of the mfERG was trained. Accuracy, sensitivity and specificity are reported.
RESULTS: 1463 eyes of 748 patients were included in the study. SVM model performance was assessed on 293 eyes from 265 patients. 55 eyes from 54 patients were identified as demonstrating HCQ retinopathy based on the clinical reference standard, 50 eyes from 49 patients were identified by the SVM. Our SVM achieves an accuracy of 85.3% with a sensitivity of 90.9% and specificity of 84.0%.
CONCLUSIONS: Machine learning approaches can be applied to mfERG analysis to identify patients at risk of retinopathy caused by HCQ therapy.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Hydroxychloroquine; Machine learning; Reference ranges; Ring ratios; SVM; mfERG

Mesh:

Substances:

Year:  2022        PMID: 35732856     DOI: 10.1007/s10633-022-09879-7

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   1.854


  18 in total

1.  Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect.

Authors:  E Cairoli; M Rebella; N Danese; V Garra; E F Borba
Journal:  Lupus       Date:  2012-05-28       Impact factor: 2.911

Review 2.  The role of antimalarial agents in the treatment of SLE and lupus nephritis.

Authors:  Senq-J Lee; Earl Silverman; Joanne M Bargman
Journal:  Nat Rev Nephrol       Date:  2011-10-18       Impact factor: 28.314

3.  Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Sara Kaprove Penn; Amy H Kao; Laura L Schott; Jennifer R Elliott; Frederico G S Toledo; Lewis Kuller; Susan Manzi; Mary Chester M Wasko
Journal:  J Rheumatol       Date:  2010-05-01       Impact factor: 4.666

4.  Chloroquine and Hydroxychloroquine Increase Retinal Pigment Epithelial Layer Permeability.

Authors:  Nicoline M Korthagen; Jeroen Bastiaans; Jan C van Meurs; Kiki van Bilsen; P Martin van Hagen; Willem A Dik
Journal:  J Biochem Mol Toxicol       Date:  2015-03-09       Impact factor: 3.642

5.  The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.

Authors:  Ronald B Melles; Michael F Marmor
Journal:  JAMA Ophthalmol       Date:  2014-12       Impact factor: 7.389

6.  Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.

Authors:  Moez Jallouli; Camille Francès; Jean-Charles Piette; Du Le Thi Huong; Philippe Moguelet; Cecile Factor; Noël Zahr; Makoto Miyara; David Saadoun; Alexis Mathian; Julien Haroche; Christian De Gennes; Gaelle Leroux; Catherine Chapelon; Bertrand Wechsler; Patrice Cacoub; Zahir Amoura; Nathalie Costedoat-Chalumeau
Journal:  JAMA Dermatol       Date:  2013-08       Impact factor: 10.282

7.  Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography.

Authors:  Jonathan S Lyons; Matthew L Severns
Journal:  Am J Ophthalmol       Date:  2007-03-06       Impact factor: 5.258

Review 8.  Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis.

Authors:  M Petri
Journal:  Lupus       Date:  1996-06       Impact factor: 2.911

Review 9.  Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review.

Authors:  G Ruiz-Irastorza; M Ramos-Casals; P Brito-Zeron; M A Khamashta
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

10.  Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial.

Authors:  Christina Charles-Schoeman; Xiaoyan Wang; Yuen Yin Lee; Ani Shahbazian; Iris Navarro-Millán; Shuo Yang; Lang Chen; Stacey S Cofield; Larry W Moreland; James O'Dell; Joan M Bathon; Harold Paulus; S Louis Bridges; Jeffrey R Curtis
Journal:  Arthritis Rheumatol       Date:  2016-03       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.